LO-020 Association between corticosteroid use and risk of avascular necrosis in patients with systemic lupus erythematosus: a nested case-control study

• Published in: Lupus science & medicine 2023-07, Vol.10 (Suppl 1), p.A17-A17
• Main Authors: Lee, Jongmin, You, Seung-Hun, Yu-Seon, Jung, Yoon-Kyoung Sung, Cho, Soo-Kyung, Sun-Young, Jung
• Format: Article
• Language: English
• Subjects: Lupus; Necrosis; Steroids
• ISSN: 2053-8790
• DOI: 10.1136/lupus-2023-KCR.20

BackgroundCorticosteroid (CS) is effective for controlling inflammatory reactions in SLE, but may have been known to increase risk of avascular necrosis (AVN) in patients with Systemic lupus erythematosus (SLE). This population-based study aims to investigate the association between cumulative dose of CS and the incidence of AVN in newly diagnosed SLE patients.MethodsWe conducted a nested case-control study using Korean National Health Insurance claims database from 2002 to 2018. Cohort of incident diagnosis of SLE (ICD10, M32) with rare intractable disease code (V136) were identified during 2007~2018. Cases, who were diagnosed for any reason with AVN (M87.0x, M87.1x, M87.3x, M87.8x, M87.9x, M90.5x (ICD-10)), were matched up to 10 controls based on gender, age (±5yrs), and date of SLE diagnosis (±6 months). Conditional logistic regression analysis was performed to calculate adjusted odds ratios (ORs) and 95% confidence intervals (CIs) of AVN occurrence associated with cumulative dose of CS [prednisolone-equivalent dose (PED)] from the date of SLE diagnosis to the index date, with adjusting for hypertension, dyslipidemia, immunosuppressants and so forth. Cumulative CS dose was categorized into 3 groups (0≤ < 4g, 4≤